Scholars Central

Research articlePublished 31 Jul 2023

Brolucizumab in Age-Related Macular Neovascularization (Brain Study): Efficacy, Optical Coherence Tomography Biomarkers and Safety Profile over 18 Months

Authors: Supriya Dabir, Arthi Mohankumar, Manoj Khatri, Mohan Rajan

Journal of Clinical and Experimental Ophthalmology

Volume 14 · Issue 4 · Pages 1–5

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Background: Brolucizumab is a new anti-Vascular Endothelial Growth Factor (anti-VEGF) in treatment of neovascular Age-related Macular Degeneration (nAMD) and Idiopathic Polypoidal Choroidal Vasculopathy (IPCV). Materials and methods: A retrospective, consecutive, interventional studies from a tertiary eye hospital, where treatment naive and treatment switch patients were included. They underwent intravitreal injection Brolucizumab. Decision to reinject was made on presence of fluid on Spectral Domain Optical Coherence Tomography (SD OCT) or worsening of vision at follow-up. Outcome measures were change in Best Corrected Visual Acuity (BCVA), Central Subfield Thickness (CST) and changes in fluid (sub-retinal/intra-retinal/sub retinal pigment epithelium fluid) levels, Optical Coherence Tomography (OCT) biomarkers and safety analysis. Results: A total of 59 eyes of 50 patients with a total of 132 intravitreal injections were included. There was a statistically significant improvement (p<0.05) in BCVA from baseline in treatment naive patients (mean BCVA at baseline 0.6 ± 0.41 and 0.37 ± 0.56). Mean baseline CST of all patients significant reduced from 582.92 ± 233.11 μm at baseline to 474.06 ± 252.89 μm at final treatment visit. Thirty-eight percentages of patients showed complete resolution of Sub- retinal Hyper-reflective Material (SHRM) after single injection. Interval between each subsequent injection increased from mean of 67 to 96 days in treatment switch and 47 to 151 days in treatment naive patients. Conclusion: Brolucizumab promises reduced number of injections without any vision threatening complications.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Clinical and Experimental Ophthalmology.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Clinical and Experimental Ophthalmology
  • SubjectOphthalmology & Optometry
  • BylineArticles whose byline prints “Supriya Dabir”
  • BylineArticles whose byline prints “Arthi Mohankumar”
  • BylineArticles whose byline prints “Manoj Khatri”
  • BylineArticles whose byline prints “Mohan Rajan”